The financial system has gotten much more complex, but many financial regulations are from the 1930's and 40's, notes Andrew Lo, professor at the MIT Sloan School of Management. Lo helped come up with the idea for the U.S. Office of Financial Regulation, which was created by the 2010 Dodd Frank Act. Nonetheless, much of Dodd Frank is way too long and difficult for anyone to understand, Lo contends. 'That wasn't so much an update as it was a piling on of new regulations,' Lo says of Dodd Frank.

The MIT Sloan School of Management's Institute for Work and Employment Research, The MIT Political Science Department and Boston Review convened a diverse group of faculty and community leaders to discuss the lessons that can be drawn from the astonishing events involving Market Basket. Excerpts Professor Andrew Lo's comments from the panel on Finance, Marketing and Operations are included in this article.

New Regulatory Thinking Redux. Too much innovation caused the financial crisis; too little policy innovation followed it. Professor Andrew Lo comments on new regulatory thinking.

Natixis and MIT team up to build individual benchmarks based on investor behavior. Dr. Andrew Lo, Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the Laboratory for Financial Engineering (LFE), will lead the project, which will be conducted using Natixis data (the firm has collected several years worth of data that track the behavior of individual investors, financial advisors and institutional investors, and that is based on responses to more than 500 survey questions by more than 30,000 participants).  The main goal of the project is to create personal, individual benchmarks that take into account individual behaviors in order to improve investor participation and performance.

The quest for a treatment that can combat Alzheimer’s remains frustrating and expensive, but Andrew Lo believes he may have a path forward. A finance professor who directs the Laboratory for Financial Engineering at the MIT Sloan School of Management, Lo thinks that a public-private partnership could solve some of the funding issues that have plagued drug discovery and development.

Researchers argue for a public-private superfund to advance many Alzheimer’s therapeutics projects in parallel.

MIT economist, Andrew W. Lo, calls for Alzheimer’s ‘megafund’.

More than 5 million Americans suffer from Alzheimer’s disease, the affliction that erodes memory and other mental capacities, but no drugs targeting the disease have been approved by the U.S. Food and Drug Administration since 2003. Now a paper by an MIT professor, Andrew W. Lo, suggests that a revamped way of financing Alzheimer’s research could spur the development of useful new drugs for the illness.

MIT finance professor, Andrew Lo, is working with banking regulators at the Office of the Comptroller of the Currency, an arm of the Treasury Department, to help build quantitative tools to find potential credit risk in the banking industry, starting with the mortgage market. The efforts of Lo, a pioneer in his field, are part of an unprecedented push at the OCC to embrace quantitative analysis. The regulator is building models, hiring financial engineers - known on Wall Street as "quants" or "strats"- and questioning banks to a far greater degree than it ever has before.

Why do investors make stupid mistakes? Why do individuals consistently underperform the very funds they invest in? Are there strategies investors can follow to avoid self-destructive behavior? Those are some of the weighty questions Financial Thought Leader Andrew Lo is trying to answer from two vantage points, one as a professor of Finance at MIT and Director of its Laboratory for Financial Engineering, the other as strategist and fund manager at his firm AlphaSimplex Group. This conversation will start with his most recent research project at MIT, titled "Artificial Stupidity"!

Creative investments could fund a huge number of new drug-development projects.

Here in the Boston area, cancer researchers abound. But there is something of a crisis in the field. As a professor/friend of mine who runs a lab here in town tells me, research has identified a host of therapeutic targets, but “results from the clinic have not produced encouraging outcomes and, to date, there have been no reliable lasting responses to therapies against many malignancies.”It seems that cancer cells are proving better than researchers thought at evasion. They evolve, adapting to treatments and circumventing them. Out-of-the-box thinking, and funding, may be what’s necessary.

Professor Andrew W. Lo discusses his proposal to use financial engineering to spread risks among investors and provide financial incentives to develop successful cancer treatments. He explains how the cancer megafund works, and how investors can make good money in finding a cure for cancer.